In addition, both immune checkpoint inhibitors and CAR-T therapy rely on killer T cells, but the GBM TME exhibits mass macrophage infiltration, which includes phenotypically suppressive CD163+ M2 to undifferentiated M0 macrophages, particularly in the mesenchymal molecular GBM subtype (30). Here, CD163 is linked to glioblastoma.